Predictive factor for achieving discontinuation of tofacitinib
rheumatoid, low disease
REMISSION, DISEASE, DISEASE, PGA
As shown in Sankey diagram describing proportion of patients per CDAI disease activity category over time in the subgroup. (A) Bio-naïve patients (n=16), (B) bio-experienced patients (n=21). Data are n (%). CDAI, Clinical Disease Activity Index.In addition, the patients who had high titers of ACPA were less likely to achieve it, although these were not statistically significant (p=0.0569). These trends were not observed in the MTX discontinuation group, where patients who were able to maintain remission following MTX discontinuation were characterised by high matrix metalloproteinase-3 before starting tofacitinib (On the other hand, when comparing the patients’ backgrounds at week 52 (Key factors at the drug discontinuation of tofacitinib or methotrexate to achieve sustained low disease acitivityData reported as mean (SD).CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score 28 Joint; EGA, Evaluator’s Global Assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LDA, low disease acitivity; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; PGA, Patient’s Global Assessment.Serial changes in the CDAI and clinical remission according to CDAI after discontinuation of tofacitinib or methotrexate in the subgroup. Spaghetti plot (black lines: mean value, grey lines: the values of individual patients) and bar graph of remission rate are shown. (A) RF lower titre group (left) and higher titre group (right) in the tofacitinib discontinuation arm. (B) RF lower titre group (left) and higher titre group (right) in the methotrexate discontinuation arm. Data are mean (SEM) and %. CDAI, Clinical Disease Activity Index; RF, rheumatoid factor.